本团队与中国医学科学院肿瘤医院胸外科高树庚副院长、中科院上海细胞与生化研究所生物信息中心主任石建涛研究员、中山大学附属第七医院基础研究中心钱志荣教授进行长期合作，团队成员覆盖分子病理实验室、胸外科、基础研究和生物信息学专家。团队专注肺癌发生发展分子机制研究，涵盖肺鳞癌驱动基因、肺癌甲基化应用于早期诊断和肺癌分子诊断临床转化研究，从早期诊断、驱动基因鉴定到晚期肺癌综合治疗生物标记物研究等全方位研究肺癌发生发展机制，并实现临床转化应用。

1.       2019年北京市科技新星

2.       国家自然科学基金青年项目，2014-2017，项目负责人

3.       中国医学科学院肿瘤医院基本科研业务费，2013-2016，项目负责人

4.       中国医学科学院医学与健康科技创新工程青年团队项目子课题，2017-2020，项目负责人

5.       国家科技重大专项-重大新药创制，2013-2015，项目骨干

6.       国家高技术研究发展计划（863），2014-2017，项目骨干

1.       2019年北京市科技新星

2.       国家自然科学基金青年项目，2014-2017，项目负责人

3.       中国医学科学院肿瘤医院基本科研业务费，2013-2016，项目负责人

4.       中国医学科学院医学与健康科技创新工程青年团队项目子课题，2017-2020，项目负责人

5.       国家科技重大专项-重大新药创制，2013-2015，项目骨干

6.       国家高技术研究发展计划（863），2014-2017，项目骨干

第一及通讯作者文章：

1.       Guo L,Song P, Xue X, Guo C, Han L, Fang Q, Ying J, Gao S, Li W. Variation ofProgrammed Death Ligand 1 Expression After Platinum-based NeoadjuvantChemotherapy in Lung Cancer. J Immunother. 2019 Jul/Aug;42(6):215-220.

2.       SongP, Zhang F, Li Y, Yang G, Li W*,Ying J*, Gao S*. ConcomitantTP53 mutations with response to crizotinib treatment in patients withALK-rearranged non-small-cell lung cancer. Cancer Med. 2019 Apr;8(4):1551-1557. (Co-correspondingauthor)

3.       Li W, Song P, Guo L, Liu X, Guo C, Ying J, Gao S. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonalantibody in non-small cell lung cancer patients. Thorac Cancer. 2019 Feb;10(2):175-182.

4.       Li W, Zhang J, Guo L, Chuai S, Shan L and Ying J.Combinational analysis of FISH and immunohistochemistry reveals rare genomicevents in ALK fusion patterns in NSCLC and responds to crizotinib treatment. Journal of Thoracic Oncology. 2017. Jan;12(1):94-101. doi: 10.1016/j.jtho.2016.08.145.

5.       Wenbin Li, Zhihui Zhang, Lei Guo, Tian Qiu, Yun Ling, Jian Cao,Huiqin Guo, Huan Zhao, Lin Li and Jianming Ying. Assessment of cytology basedmolecular analysis to guide targeted therapy in advanced non-small-cell lungcancer. Oncotarget. 2015 Dec 18. doi:10.18632/oncotarget.6671.

6.       Li W, Qiu T, Ling Y, Guo L, Li L, Ying J. Molecular pathological epidemiology of colorectal cancer in Chinesepatients with KRAS and BRAF mutations. Oncotarget. 2015,6(37): 39607-39613.

7.       Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N.Colorectal carcinomas with KRAS codon12 mutation are associated with more advanced tumor stages. BMC Cancer. 2015 May 1; 15(1):340. doi:10.1186/s12885-015- 1345-3.

8.       Wenbin Li, WenxueZhi, Shuangmei Zou, Tian Qiu, Yun Ling, Lin Shan, Susheng Shi, Jianming Ying.Distinct clinicopathological patterns of mismatch repair status in colorectalcancer stratified by KRAS mutations. Plos One. 2015. June 4. DOI:10.1371/journal.pone.0128202.

9.       Wenbin Li, Xinghua Zhang, Yibie Xie,Jiancheng Liu, Yongkang Chen, Qiang Feng, Yi Wang, Wei Yuan, Jie Ma. G-CSF is akey modulator of MDSC and could be a potential therapeutic target incolitis-associated colorectal cancers.  Protein & Cell. 2016 Feb; 7(2):130-40.

10.    Li W, Guo L, Bi X, Ma J,Zheng S. Immunohistochemistryof p53 and Ki-67 and p53 mutation analysis in renal epithelioid angiomyolipoma. Int J Clin Exp Pathol. 2015 Aug 1; 8(8):9446-51.

11.   Wenbin Li, Wei Yuan, Fu-Jian Xu, Chen Zhao, Jie Ma and Qi-MinZhan. Functional studyof dextran-graft-poly((2-dimethylamino) ethylmethacrylate) gene delivery vector for tumor therapy. Journal of Biomaterials Application. 2013, Jul. 28(1): 125-35.

12.   Wen-bin Li, Chen Zhao, Wei Yuan, Jie Ma. Evaluation of the NovelNanoparticles HPC-g-PDMAEMA as Gene Delivery System. Chin Pham J. 2010 July, 45(14): 1080-1084.

13.   Lei Guo#,Wenbin Li#,Xinxin Zhu, Yun Ling, TianQiu, Lin Dong, Yi Fang, Hongying Yang and Jianming Ying. PD-L1 expression and CD274 gene alteration in triple-negativebreast cancer: implication for prognostic biomarker. Springerplus. 2016. 5:805. DOI 10.1186/s40064-016-2513-x.

其他作者文章：

14.   RongL, Liu Y, Hui Z, Zhao Z, Zhang Y, Wang B, Yuan Y, Li W, Guo L, Ying J, Song Y, Wang L, Zhou Z, Xue L, Lu N. PD-L1 expression and its clinicopathological correlation in advancedesophageal squamous cell carcinoma in a Chinese population. Diagn Pathol. 2019 Jan 26;14(1):6.

15.   Zou SM, Li WH, Wang WM, Li WB, Shi SS, Ying JM, Lyu N.The gene mutational discrepancies between primary and paired metastaticcolorectal carcinoma detected by next-generation sequencing. J Cancer Res ClinOncol. 2018. Nov;144(11):2149-59.

16.   Li Y,Gao L, Ma D, Qiu T, Li W, Li W, GuoL, Xing P, Liu B, Deng L, Fu J, Li J, Yu Y, Ying J. Identification of MET exon14 skipping by targeted DNA-and RNA-based next-generationsequencing in pulmonary sarcomatoid carcinomas. Lung Cancer. 2018 Aug;122:113-119.

17.   SongP, Guo L, Li W, Zhang F, Ying J, GaoS. ClinicopathologicCorrelation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltratingImmune Cells in Patients With Non-Small Cell Lung Cancer. J Immunother. 2019 Jan;42(1):23-28. 

18.   Li Y,Zhang T, Zhang J, Li W, Yuan P, XingP, Zhang Z, Chuai S, Li J, Ying J. Response tocrizotinib in advanced ALK-rearranged non-small cell lung cancers withdifferent ALK-fusion variants. Lung Cancer. 2018 Apr;118:128-133.

19.   Sun Y,Yang L, Wang C, Zhao D, Cai J, Li W,Zhang W, Huang J, Zhou A. Prognostic factors associated with locally advanced gastriccancer patients treated with neoadjuvant chemotherapy followed by surgical resection. Oncotarget. 2017 Sep 6;8(43):75186-75194.

20.   ZhangJ, Guo L, Liu X, Li W, Ying J. MET overexpression, gene amplification and relevant clinicopathologicalfeatures in gastric adenocarcinoma. Oncotarget.2017 Feb 7;8(6):10264-10273.

21.   LingY, Yang X, Li W, Li Z, Yang L, QiuT, Guo L, Dong L, Li L, Ying J, Lin D. Overexpression of mutant EGFR proteinindicates a better survival benefit from EGFR-TKI therapy in non-small celllung cancer. Oncotarget. 2016. Jul13. doi: 10.18632/oncotarget.10594.

22.   XueLi, Wenbin Li, Qinhua Yang, XiaoqunGong, Weisheng Guo, Chunhong Dong, Junqing Liu, Lixue Xuan and Jin Chang. Rapidand Quantitative Detection of Prostate Specific Antigen with a Quantum DotNanobeads-Based Immunochromatography Test Strip. ACS Applied Materials & Interfaces. 2014 May 14;6(9):6406-14.doi: 10.1021/am5012782.

23.   SongT, Liu J, Li W, Li Y, Yang Q, GongX, Xuan L, Chang J. Self-healing encapsulation strategy for preparing highlystable, functionalized quantum-dot barcodes. ACS Applied Materials & Interfaces. 2014. 6(4): 2745-52.

24.   ShanL, Wang Z, Guo L, Sun H, Qiu T, Ling Y, LiW, Li L, Liu X, Zheng B, Lu N, Ying J. Concurrence of EGFRamplification and sensitizing mutations indicate a better survival benefit fromEGFR-TKI therapy in lung adenocarcinoma patients. LungCancer. 2015 Sep; 89(3):337-42.

25.   ShanL, Qiu T, Ling Y, Guo L, Zheng B, Wang B, LiW, Li L, Ying J. Prevalence andClinicopathological Characteristics of HER2 and BRAF Mutation in ChinesePatients with Lung Adenocarcinoma. Plos One.2015 Jun 23; 10(6):e0130447.

26.   Qiu T,Lu H, Guo L, Huang W, Ling Y, Shan L, LiW, Ying J, Lv N. Detection of BRAFmutation in Chinese tumor patients using a highly sensitive antibodyimmunohistochemistry assay. Sci Rep. 2015 Mar 18; 5:9211.

27.   Z.H.Wang, W.B. Li, J. Ma, G.P. Tang,W.T. Yang and F.J. Xu. Functionalized Nonionic Dextran Backbones by AtomTransfer Radical Polymerization for Efficient Gene Delivery. Macromolecules. 2011, 44: 230-239.

F.J. Xu, M.Y. Chai, W.B. Li, Y. Ping, G.P. Tang, W.T. Yang, J. Ma, and F.S. Liu.Well-Defined Poly(2-hydroxyl-3-(2-hydroxyethylamino) propyl methacrylate)Vectors with Low Toxicity and High Gene Transfection Efficiency. Biomacromolecules.2010, 11(6): 1437-1442.